Alexandria Real Estate Equities, Inc. is a real estate investment trust based in Pasadena, California that invests in office buildings and laboratories leased to tenants in the life science and technology industries. Properties are generally located near universities to attract tenants. The company owns several major technology/biotechnology office campuses including the 740,972 square foot Alexandria Center for Life Science in Manhattan, and the 2,365,487 square foot Alexandria Center at Kendall Square and the 1,181,635 square foot Technology Square (Cambridge, Massachusetts) in the Boston area.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ARE | ALEXANDRIA REAL ESTATE EQUITIES, INC. | 2025-10-16 18:50:40 | 75.28 | 0.05 | 0.07 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ARE | 0001035443 | ALEXANDRIA REAL ESTATE EQUITIES, INC. | US0152711091 | MGCJBT4MKTQBVLNUIS88 | 954502084 | NYSE | 6798 | Real Estate Investment Trusts | 1231 | MD | 26 NORTH EUCLID AVENUE | PASADENA | CA | 91101 | UNITED STATES | US | 6265780777 | 26 NORTH EUCLID AVENUE, PASADENA, CA, 91101 | 26 NORTH EUCLID AVENUE, PASADENA, CA, 91101 | ALEXANDRIA REAL ESTATE EQUITIES INC | Real estate investment trust | 1994 | — | 552 | https://www.are.com/ | 20,300,000,000 | 170,100,000 | 172,958,948 | Alexandria Real Estate Equities, Inc. is a real estate investment trust based in Pasadena, California that invests in office buildings and laboratories leased to tenants in the life science and technology industries. Properties are generally located near universities to attract tenants. The company owns several major technology/biotechnology office campuses including the 740,972 square foot Alexandria Center for Life Science in Manhattan, and the 2,365,487 square foot Alexandria Center at Kendall Square and the 1,181,635 square foot Technology Square (Cambridge, Massachusetts) in the Boston area. | 2025-10-10 19:39:10 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 20,300,000,000 | 800,000,000 | 4.1026 | 173,091,762 | -1,876,497 | -1.0725 |
| 2023 | 19,500,000,000 | -4,000,000,000 | -17.0213 | 174,968,259 | 1,881,172 | 1.0868 |
| 2022 | 23,500,000,000 | -4,000,000,000 | -14.5455 | 173,087,087 | 13,143,756 | 8.2178 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Marc E. Binda | Chief Financial Officer, Treasurer | 2024 | 650,000 | 950,000 | 4,009,501 | 0 | 48,598 | 5,787,452 |
| Daniel J. Ryan | Director, Co-President | 2024 | 790,000 | 1,750,000 | 6,469,088 | 0 | 46,000 | 9,129,763 |
| Joel S. Marcus | Founder, Executive Chairman | 2024 | 1,300,000 | 2,030,000 | 9,413,563 | 2,925,000 | 183,721 | 17,727,276 |
| Peter M. Moglia | Chief Investment Officer, Chief Executive Officer | 2024 | 810,000 | 0 | 7,546,605 | 1,822,500 | 50,857 | 10,275,115 |
| Hunter L. Kass | Director, Co-President | 2024 | 700,000 | 1,750,000 | 6,205,864 | 0 | 46,000 | 8,708,376 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 552 |
| 2023 | 568 |
| 2022 | 593 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 3,116,394,000 | 2,885,699,000 | 2,588,962,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | 168,359,000 | 199,354,000 | 177,278,000 |
| Operating Expenses | 2,688,910,000 | 2,687,325,000 | 2,125,066,000 |
| Operating Income | 2,096,294,000 | — | — |
| Net Income | 322,949,000 | 103,639,000 | 521,660,000 |
| Earnings Per Share Basic | 1.8 | 0.54 | 3.18 |
| Earnings Per Share Diluted | 1.8 | 0.54 | 3.18 |
| Weighted Average Shares Outstanding Basic | 172,071,000 | 170,909,000 | 161,659,000 |
| Weighted Average Shares Outstanding Diluted | 172,071,000 | 170,909,000 | 161,659,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 552,146,000 | 618,190,000 | 825,193,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 6,409,000 | 8,211,000 | 7,614,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | — | — | — |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 39,558,000 | 26,560,000 | 23,186,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | — | — | — |
| Total Assets | 37,527,449,000 | 36,771,402,000 | 35,523,399,000 |
| Accounts Payable | 2,654,351,000 | 2,610,943,000 | 2,471,259,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 600,034,000 | 32,000 | 30,000 |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | — | — | — |
| Long Term Debt | 12,244,374,000 | 11,315,642,000 | 10,159,762,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | 15,128,988,000 | 14,148,409,000 | 12,840,152,000 |
| Common Stock | 1,722,000 | 1,719,000 | 1,707,000 |
| Retained Earnings | — | — | — |
| Accumulated Other Comprehensive Income | -46,252,000 | -15,896,000 | -20,812,000 |
| Total Shareholders Equity | 17,889,042,000 | 18,471,175,000 | 18,972,387,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 1,202,380,000 | 1,093,473,000 | 1,002,146,000 |
| Share Based Compensation Expense | 59,634,000 | 82,858,000 | 57,740,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | — | — | — |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 37,052,000 | -798,000 | 18,960,000 |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 1,504,524,000 | 1,630,550,000 | 1,294,321,000 |
| Purchases Of Marketable Securities | 236,357,000 | 189,472,000 | 242,932,000 |
| Sales Of Marketable Securities | 173,927,000 | 183,396,000 | 198,320,000 |
| Acquisition Of Property Plant And Equipment | — | — | — |
| Acquisition Of Business | — | 0 | 0 |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -1,510,695,000 | -2,500,619,000 | -5,080,458,000 |
| Tax Withholding For Share Based Compensation | 62,413,000 | 24,592,000 | 47,289,000 |
| Payments Of Dividends | 906,996,000 | 860,176,000 | 783,026,000 |
| Issuance Of Common Stock | 27,103,000 | 103,846,000 | 2,346,444,000 |
| Repurchase Of Common Stock | 50,107,000 | — | — |
| Issuance Of Long Term Debt | 0 | 1,245,000,000 | 1,181,000,000 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -93,315,000 | 674,156,000 | 4,229,772,000 |
| Change In Cash | -100,924,000 | -197,204,000 | 442,748,000 |
| Cash At End Of Period | 552,146,000 | 618,190,000 | 825,193,000 |
| Income Taxes Paid | — | — | — |
| Interest Paid | 160,082,000 | 46,583,000 | 63,193,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 1.8 | 0.54 | 3.18 |
| Price To Earnings Ratio | 54.1944 | 234.7593 | 45.8082 |
| Earnings Growth Rate | 233.3333 | -83.0189 | -16.9713 |
| Price Earnings To Growth Ratio | 0.2323 | -2.8278 | -2.6992 |
| Book Value Per Share | 130.1699 | 132.3686 | 140.3154 |
| Price To Book Ratio | 0.7494 | 0.9577 | 1.0382 |
| Ebitda | 1,711,167,000 | 1,271,316,000 | 1,618,009,000 |
| Enterprise Value | 29,077,788,050 | 32,363,617,930 | 32,883,465,530 |
| Dividend Yield | 0.054 | 0.0397 | 0.0333 |
| Dividend Payout Ratio | 2.8085 | 8.2997 | 1.501 |
| Debt To Equity Ratio | 0.718 | 0.6126 | 0.5355 |
| Capital Expenditures | 1,215,378,000 | 1,096,847,000 | 998,903,000 |
| Free Cash Flow | 289,146,000 | 533,703,000 | 295,418,000 |
| Return On Equity | 0.0181 | 0.0056 | 0.0275 |
| One Year Beta | 0.8245 | 1.4371 | 0.921 |
| Three Year Beta | 0.9947 | 0.9507 | 0.9536 |
| Five Year Beta | 0.9799 | 0.9573 | 0.8806 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Woronoff Michael A | Director | 2025-09-30 | 510 | A | 20,960 |
| Hash Steve | Director | 2025-09-30 | 330 | A | 25,707 |
| Moglia Peter M | Chief Executive Officer | 2025-09-30 | 743 | D | 281,509 |
| Gavinet Andres | Chief Accounting Officer | 2025-09-15 | 1,091 | D | 88,165 |
| Ryan Daniel J | Co-President and RMD | 2025-09-15 | 2,927 | D | 234,959 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas R Carper | Senator | 2021-09-01 | Sale (Partial) | 2021-08-04 | Spouse | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2021-05-17 | Purchase | 2020-04-02 | Spouse | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2020-12-02 | Purchase | 2020-11-20 | Spouse | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2020-09-01 | Sale (Partial) | 2020-08-21 | Spouse | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2020-05-04 | Purchase | 2020-04-02 | Spouse | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Ritchie John Torres | 2025-08-20 | NY15 | Purchase | 2024-09-26 | — | $1,001 - $15,000 |
| Rob Bresnahan | 2025-06-09 | PA08 | Sale | 2025-05-15 | — | $1,001 - $15,000 |
| Rob Bresnahan | 2025-03-27 | PA08 | Purchase | 2025-02-25 | — | $1,001 - $15,000 |
| Lois Frankel | 2023-10-10 | FL22 | Sale | 2023-09-08 | — | $1,001 - $15,000 |
| Daniel Goldman | 2023-08-13 | NY10 | Sale | 2023-07-12 | — | $15,001 - $50,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Silicon Valley Capital Partners | 2025-06-30 | 1,017 | 14 | 72.6429 |
| WHITTIER TRUST CO OF NEVADA INC | 2025-06-30 | 20,043 | 276 | 72.6196 |
| WHITTIER TRUST CO | 2025-06-30 | 15,975 | 220 | 72.6136 |
| OSTERWEIS CAPITAL MANAGEMENT INC | 2025-03-31 | 463 | 5 | 92.6 |
| RHUMBLINE ADVISERS | 2025-03-31 | 30,743,847 | 332,331 | 92.5097 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| ETF Series Solutions | 2025-07-31 | Aptus Large Cap Enhanced Yield ETF | DUBS | 556 | 42,495.08 | 0.0178 |
| Pacer Funds Trust | 2025-07-31 | Pacer Trendpilot US Large Cap ETF | PTLC | 9,522 | 727,766.46 | 0.0218 |
| Pacer Funds Trust | 2025-07-31 | Pacer MSCI World Industry Advantage ETF | GLBL | 4 | 305.72 | 0.033 |
| Pacer Funds Trust | 2025-07-31 | Pacer Metaurus US Large Cap Dividend Multiplier 400 ETF | QDPL | 2,815 | 215,150.45 | 0.0198 |
| ETF Series Solutions | 2025-07-31 | AAM S&P 500 High Dividend Value ETF | SPDV | 16,530 | 1,263,387.9 | 1.4588 |